About US
Contact us
-
Pfizer cuts physician payments by about $17M in 2012It's not that there is no free lunch for doctors, there are just fewer of them. Some members of Big Pharma are significantly cutting their budgets for spending on docs as lost sales and resulting d2013/4/15
-
Pfizer Ventures backs effort to amp up orphan-drug developmentDavid Mott, ex-CEO of MedImmune and a high-profile biotech partner at New Enterprise Associates, has led the way toward an orphan drug accelerator also backed by Pfizer Ventures. The Cambridge, MA-ba2013/4/12
-
Eli Lilly to lay off hundreds in sales as Cymbalta nears edge of patent cliffHere is a business reality that hundreds of Eli Lilly ($LLY) sales employees are going to have to align themselves with quite soon: They are about to lose their jobs. With its best-selling drug, th2013/4/12
-
Lilly settles long-running lawsuit tying Cymbalta to teen's suicideEli Lilly ($LLY) has battled to protect its best-selling drug, the antidepressant Cymbalta, against generic competition but has decided not to stand and fight a lawsuit tying it to the suicide of a 12013/4/11
-
Vivus investor says FDA move on Qsymia isn't enoughAt least one Vivus ($VVUS) shareholder isn't convinced that loosening FDA restrictions on a new obesity pill will fuel sales in any significant way. First Manhattan, which owns a 9.1% stake in the dr2013/4/11
-
FDA approves morning-sickness drug withdrawn in 1980s safety scareThe FDA has resurrected a morning-sickness treatment that went not-so-gently into the good night 30 years ago, on unfounded worries about birth defects. Diclegis, a tablet made by Canadian-based Duche2013/4/10
-
J&J releases more Doxil to the marketJohnson & Johnson ($JNJ) and the FDA sprang into action in 2011 when J&J's popular chemo drugDoxilbecame hard to get because of problems with the contract manufacturer. While the FDA looked fo2013/4/10
-
S&P doesn't buy AstraZeneca CEO's revamp planStandard & Poor's is not impressed with AstraZeneca's jump-start plan. The ratings agency cut the U.K.-based drugmaker's credit ratings, citing CEOPascal Soriot's strategy update last month,Reute2013/4/9
-
Roche inks $392M Huntington's disease pact with IsisRoche ($RHHBY) has stepped up with a $392 million deal designed to marry its work on new technology for delivering brain treatments with Isis' ($ISIS) antisense programs for Huntington's disease. In2013/4/9
-
Judge gives FDA 30 days to make Teva's Plan B available to adolescents OTCA federal judge has told the FDA to do exactly what the agency tried to do two years ago: make the "morning after"birth controlpill freely available to girls of all ages without a prescription. U.S2013/4/8